Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fluicell ABFRA:5J90 -4.20%54 Net Current Asset Value is €0.23 as of Jun. 2026. GuruFocus rates FRA:5J90 with a GF Score™ of 54/100 and a GF Value™ of €6.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 935 Biotechnology companies, Fluicell AB ranks worse than 77.86% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Fluicell AB's net current asset value per share for the quarter that ended in Jun. 2026 was €0.23.
The historical rank and industry rank for Fluicell AB's Net Current Asset Value or its related term are showing as below:
FRA:5J90'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.36 Med: 5.12 Max: 500
Current: 13
During the past 11 years, the highest Price-to-Net-Current-Asset-Value Ratio of Fluicell AB was 500.00. The lowest was 1.36. And the median was 5.12.
FRA:5J90's Price-to-Net-Current-Asset-Value is ranked worse than 77.86% of 935
companies
in the Biotechnology industry
Industry Median: 4.74
vs FRA:5J90: 13.00
Fluicell AB (FRA:5J90) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Fluicell AB Net Current Asset Value Related Terms
Fluicell AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Fluicell AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5J90 vs VRTX, REGN, MRNA: Net Current Asset Value Comparison
For the Biotechnology subindustry, Fluicell AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Fluicell AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €0.23 mean?
Fluicell AB (FRA:5J90) has a Net Current Asset Value of €0.23 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #728 out of 935 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Fluicell AB's Net Current Asset Value too high?
Fluicell AB's current Net Current Asset Value is €0.23. Based on the distribution chart, Fluicell AB ranks #728 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #728 out of 935 companies for Net Current Asset Value. This places Fluicell AB in the lower half of its industry. The industry median Net Current Asset Value is 4.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.74, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current Net Current Asset Value is €0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Possible Value Trap. The stock's GF Value™ is €6.37, compared to a current price of €2.73 — trading 57.1% below its estimated fair value. The current Net Current Asset Value is €0.23. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current Net Current Asset Value is €0.23 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (FRA:5J90) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of €2.73 is trading 57.1% below its estimated GF Value™ of €6.37.
GuruFocus considers Fluicell AB to be Possible Value Trap.
Key valuation signals for FRA:5J90:
Net Current Asset Value: €0.23
GF Value™: €6.37 vs. price of €2.73 (57.1% below fair value)
No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company specializing in high-resolution 3D bioprinting and single-cell technology. Its proprietary Biopixlar platform enables precise, nozzle-based printing of living cells to create complex human tissue models. The company operates through two main areas: contract research services and product development. Its contract research division provides human tissue-based screening models for drug development, with a focus on cardiac safety and kidney disease, serving pharmaceutical and biotechnology companies. Its regenerative medicine efforts target type 1 diabetes, exploring cell-based therapies to restore insulin production. Fluicell generates revenue primarily by offering bioprinting services and tissue models to research partners and through sales of its Biopixlar instruments and related consumables. The company is headquartered in Sweden and serves customers in the global life science and pharmaceutical research market.
54GF Score
Get the complete analysis for FRA:5J90
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5J90 has been successfully added to your 
